Profile data is unavailable for this security.
About the company
Glenmark Pharmaceuticals Limited is an India-based research-led, global pharmaceutical company. The Company hosts a diverse portfolio spanning branded, generics, and over the counter (OTC) segments. The Company is focused on the therapy areas of Respiratory, Dermatology and Oncology. The Company also has a regional/country-specific presence in other therapeutic areas like diabetes, cardiovascular and oral contraceptives. The Company’s offerings include complex injectables and biologics, oral solids, liquids, topical products, respiratory mdi1/dpi2/nasal sprays. The Company is focused on developing products for markets such as India, Russia & CIS, Brazil, Asia and Africa. Its brands include RYALTRIS and SALMEX / ASTHMEX. RYALTRIS, the Company's first global branded specialty drug for treating symptoms of seasonal allergic rhinitis. The Company's subsidiaries include Glenmark Pharmaceuticals Inc., Ichnos Sciences Inc., and Glenmark Holding SA.
- Revenue in INR (TTM)122.48bn
- Net income in INR-10.18bn
- Incorporated1977
- Employees14.99k
- LocationGlenmark Pharmaceuticals LtdB D S MargChakala, Off Western Express HighwayAndheri (E),MUMBAI 400099IndiaIND
- Phone+91 2 240189999
- Fax+91 2 240189986
- Websitehttps://glenmarkpharma.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Concord Biotech Ltd | 10.86bn | 3.28bn | 208.31bn | 1.38k | 53.76 | 13.10 | 54.58 | 19.19 | 37.04 | 37.04 | 114.79 | 152.02 | 0.655 | 1.11 | 3.55 | 7,884,886.00 | 19.78 | -- | 21.82 | -- | 76.00 | -- | 30.20 | -- | 4.83 | 194.73 | 0.0022 | -- | 19.20 | -- | 28.33 | -- | -- | -- |
Pfizer Ltd | 22.38bn | 6.18bn | 234.75bn | 1.72k | 37.99 | 6.26 | 34.58 | 10.49 | 135.06 | 135.06 | 489.19 | 819.90 | 0.5288 | 1.83 | 11.16 | 13,004,360.00 | 14.60 | 14.22 | 17.05 | 17.71 | 65.00 | 61.37 | 27.61 | 24.05 | 4.30 | 46.21 | 0.0267 | 82.67 | -9.55 | 1.05 | -11.64 | 5.14 | 33.35 | 9.24 |
Emcure Pharmaceuticals Ltd | 72.56bn | 5.67bn | 242.76bn | 11.15k | 42.27 | 5.89 | 25.28 | 3.35 | 30.37 | 30.37 | 389.63 | 217.79 | 0.978 | 1.80 | 3.96 | 6,510,068.00 | 8.02 | 7.14 | 13.55 | 13.93 | 61.11 | 59.29 | 8.20 | 7.81 | 0.9549 | 5.25 | 0.2165 | 0.00 | 11.23 | 7.14 | -6.36 | 21.35 | -5.93 | -- |
Natco Pharma Ltd. | 45.61bn | 19.45bn | 246.23bn | 4.02k | 12.66 | 3.44 | 11.54 | 5.40 | 108.58 | 108.58 | 254.65 | 399.19 | 0.6291 | 0.8928 | 3.57 | 11,356,080.00 | 26.82 | 12.33 | 30.85 | 14.25 | 85.47 | 73.05 | 42.63 | 25.16 | 4.19 | 108.70 | 0.0283 | 18.96 | 47.72 | 13.81 | 94.09 | 16.59 | -4.71 | 14.87 |
Laurus Labs Ltd | 50.53bn | 1.31bn | 263.73bn | 6.01k | 201.06 | 6.38 | 48.37 | 5.22 | 2.43 | 2.43 | 93.70 | 76.70 | 0.602 | 1.18 | 3.06 | 8,412,186.00 | 1.55 | 10.13 | 2.52 | 16.47 | 53.44 | 47.63 | 2.58 | 12.83 | 0.5818 | 1.81 | 0.4023 | 13.00 | -16.55 | 17.07 | -79.68 | 11.36 | 21.68 | 21.67 |
J B Chemicals and Pharmaceuticals Ltd | 37.11bn | 6.11bn | 264.35bn | 5.31k | 44.27 | 8.23 | 34.40 | 7.12 | 38.45 | 38.45 | 233.33 | 206.82 | 0.9481 | 2.59 | 4.85 | 6,987,882.00 | 15.61 | 15.77 | 18.62 | 18.89 | 66.26 | 61.18 | 16.47 | 16.06 | 2.20 | 27.53 | 0.0303 | 33.08 | 10.63 | 16.22 | 34.84 | 23.36 | 40.15 | 37.42 |
Gland Pharma Ltd | 58.90bn | 6.92bn | 294.41bn | 4.22k | 42.57 | 3.35 | 27.38 | 5.00 | 41.98 | 41.98 | 357.57 | 533.41 | 0.5567 | 1.28 | 4.11 | 13,967,630.00 | 6.54 | 13.23 | 7.65 | 14.56 | 60.30 | 55.58 | 11.74 | 22.92 | 3.14 | 33.11 | 0.0358 | 7.26 | 56.29 | 22.61 | -1.10 | 11.32 | 24.02 | -- |
Suven Pharmaceuticals Ltd | 9.61bn | 2.43bn | 324.43bn | 1.05k | 133.64 | 16.40 | 106.93 | 33.75 | 9.54 | 9.54 | 37.73 | 77.71 | 0.4156 | 1.52 | 5.99 | 9,136,501.00 | 10.50 | 23.17 | 11.50 | 26.20 | 61.42 | 58.85 | 25.27 | 33.21 | 4.00 | 29.50 | 0.0191 | 18.63 | -21.56 | 22.71 | -26.99 | 22.41 | -1.83 | -- |
Piramal Pharma Ltd | 87.04bn | 453.30m | 324.55bn | 6.72k | 721.71 | 4.10 | 40.34 | 3.73 | 0.3407 | 0.3407 | 66.36 | 59.91 | 0.5799 | 1.40 | 4.88 | 12,954,040.00 | 0.302 | -- | 0.428 | -- | 63.69 | -- | 0.5208 | -- | 0.5603 | 7.49 | 0.3771 | -- | 15.39 | -- | 109.56 | -- | -- | -- |
Ajanta Pharma Ltd | 44.91bn | 8.75bn | 367.93bn | 7.84k | 42.35 | 10.01 | 36.36 | 8.19 | 69.55 | 69.55 | 356.94 | 294.36 | 0.9738 | 1.33 | 4.16 | 5,725,128.00 | 18.97 | 16.61 | 23.29 | 20.47 | 75.77 | 73.22 | 19.48 | 19.31 | 2.13 | 49.88 | 0.0088 | 31.20 | 12.45 | 15.41 | 38.81 | 16.10 | -14.97 | 10.76 |
IPCA Laboratories Ltd | 85.33bn | 6.61bn | 399.22bn | 17.34k | 60.37 | 5.96 | 37.42 | 4.68 | 26.07 | 26.07 | 336.37 | 264.10 | 0.7483 | 1.12 | 4.78 | 4,922,642.00 | 5.88 | 10.33 | 9.00 | 13.52 | 67.36 | 59.16 | 7.85 | 12.25 | 1.32 | 25.33 | 0.129 | 12.86 | 23.39 | 15.35 | 16.13 | 4.24 | 17.90 | 21.67 |
GlaxoSmithKline Pharmaceuticals Limited | 35.60bn | 6.75bn | 401.43bn | 3.21k | 59.84 | 24.00 | 53.99 | 11.27 | 39.60 | 39.60 | 209.31 | 98.74 | 1.01 | 2.59 | 14.85 | 11,088,370.00 | 19.24 | 11.01 | 36.09 | 17.88 | 61.70 | 55.77 | 18.96 | 12.25 | 1.38 | 554.80 | 0.0088 | 192.07 | 6.21 | 2.00 | -2.91 | 5.78 | -36.02 | 9.86 |
Glenmark Pharmaceuticals Ltd | 122.48bn | -10.18bn | 413.80bn | 14.99k | -- | 4.90 | -- | 3.38 | -36.13 | -31.05 | 434.11 | 299.29 | 0.6951 | 1.53 | 4.04 | 8,171,082.00 | -5.64 | 1.02 | -8.51 | 1.43 | 65.64 | 59.47 | -8.11 | 1.43 | 1.00 | 2.56 | 0.1741 | 56.98 | 1.98 | 3.67 | -1,018.93 | -- | -5.89 | 4.56 |
Abbott India Ltd | 60.66bn | 12.85bn | 576.17bn | 3.81k | 44.85 | 16.36 | 42.47 | 9.50 | 604.57 | 604.57 | 2,854.72 | 1,657.05 | 1.27 | 5.32 | 15.71 | 15,904,690.00 | 26.82 | 20.92 | 36.97 | 28.59 | 45.09 | 44.20 | 21.18 | 17.26 | 1.71 | 131.36 | 0.0169 | 77.06 | 9.35 | 9.72 | 26.52 | 21.68 | 31.08 | 52.32 |
Holder | Shares | % Held |
---|---|---|
HSBC Global Asset Management (Hong Kong) Ltd.as of 31 Dec 2023 | 9.95m | 3.53% |
Mirae Asset Investment Managers (India) Pvt Ltd.as of 31 Oct 2024 | 9.46m | 3.35% |
Norges Bank Investment Managementas of 30 Jun 2024 | 9.18m | 3.25% |
Capital Research & Management Co. (World Investors)as of 30 Sep 2024 | 8.76m | 3.10% |
HDFC Asset Management Co. Ltd. (Invt Mgmt)as of 31 Oct 2024 | 8.70m | 3.08% |
The Vanguard Group, Inc.as of 06 Nov 2024 | 5.52m | 1.96% |
Dimensional Fund Advisors LPas of 07 Nov 2024 | 3.74m | 1.33% |
Aditya Birla Sun Life Amc Ltd. (Investment Management)as of 31 Oct 2024 | 3.18m | 1.13% |
Invesco Asset Management (India) Pvt Ltd.as of 31 Oct 2024 | 3.05m | 1.08% |
BlackRock Fund Advisorsas of 07 Nov 2024 | 2.13m | 0.75% |